Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma

Exclusion Criteria

• •ECOG performance status 0-2
• •Life expectancy ≥ 12 weeks
• •ANC ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Hemoglobin ≥ 9 g/dL
• •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• •AST and ALT ≤ 3.0 times ULN (5 times ULN if liver has tumor involvement)
• •Creatinine clearance ≥ 45 mL/min
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 3 months after completion of study therapy
• •No active infection or other serious illness that would preclude study participation
• •No weight loss ≥ 10% within the past 6 weeks
• •No peripheral neuropathy (e.g., diabetic neuropathy) ≥ CTC grade 1
• •Must be able to take concurrent vitamin B12 and folic acid
• •PRIOR CONCURRENT THERAPY:
• •No more than 1 prior chemotherapy regimen for metastatic disease
• •More than 12 months since prior adjuvant therapy
• •More than 30 days since prior drug that has not received regulatory approval
• •More than 30 days since prior radiation therapy and recovered (alopecia allowed)
• •Prior standard postoperative adjuvant radiation therapy for rectal cancer allowed
• •No prior radiation therapy to ≥ 25% of bone marrow
• •No prior oxaliplatin or pemetrexed disodium
• •No NSAIDs or acetylsalicylic acid 2 days before (5 days for long-acting agents \[e.g., piroxicam\]), during, and for 2 days after each dose of pemetrexed disodium
• •No concurrent nonpalliative radiation therapy or surgery for cancer
• •No concurrent hormonal cancer therapy (except medroxyprogesterone)
• •No other concurrent experimental medications (except thymidine)
• •No other concurrent chemotherapy or immunotherapy
• •No other concurrent anticancer therapy
• •Concurrent palliative radiation therapy allowed for small areas of painful metastasis that cannot be managed adequately by systemic or local analgesics